16 Nov 2021 Research
John Goldman Fellowships for 2022 open in December
Leukaemia UK is delighted to announce that we are funding more ground-breaking research in 2022, by continuing our investment in early career scientists and clinicians for our prestigious John Goldman Fellowships.
Applications for the annual fellowship programme open on 1st December 2021 to scientists and clinician-scientists working in UK universities, research institutions or hospitals. There is no age limit, although the fellowship programme is designed to provide funding at a critical point in a researcher’s career – the transition to becoming an independent researcher.
We have now increased the maximum award available to £150,000, to span a minimum 18-month and maximum 2-year period.
The John Goldman Fellowships were created in honour of Professor John Goldman (1938 – 2013), a renowned haematologist and pioneer in the treatment of leukaemia.
The awards are aimed at early career researchers with a passion for science, a desire to develop new ideas and translate scientific advances into clinical practice.
Successful applicants will show that they are the potential scientific/clinical leaders of the future. Their proposed research project must be novel with the capacity to make advances in our knowledge of leukaemia and related diseases and the development of new and kinder treatments.
Find out more about the 2021 John Goldman Fellows and their research projects:
Dr Daniel Coleman- AML: Developing kinder treatments by targeting mutated RAS
Dr Pramila Krishnamurthy – Understanding how donor lymphocyte infusion can prevent leukaemia patients from relapsing after a stem cell transplant
Dr Samanta Mariani – Investigating the role of macrophages in infant leukaemia
Dr William Grey (pictured above) – Could targeting the repertoire of proteins in AML lead to improved survival for the most at risk patients?
Dr Giulia Orlando (pictured right) – The role of RAS in Juvenile Myelomonocytic Leukaemia-finding new therapies?
Applications for the 2022 fellowships close on 31st January 2022. Find out more about the application process.
Related posts
24 September 2021
Leading leukaemia charities call on Rishi Sunak not to cut financial lifeline for blood cancer patients
Leukaemia Care, Leukaemia UK and Leukaemia and Lymphoma Northern Ireland, have written to the Chancellor urging him to realise the devastating impact the end of the Coronavirus Job Retention Scheme will have on the clinically extremely vulnerable (CEV).
18 September 2025
1 in 4 leukaemia patients in England experiences an avoidable delay in diagnosis
A first of its kind study, commissioned by Leukaemia UK, has revealed that a quarter (26%) of leukaemia patients in England experience avoidable delays in their diagnosis, resulting in a…
19 June 2023
Leukaemia UK research paves the way for personalised lymphoma treatment
Despite promising trials, standard treatment for diffuse large B-cell lymphoma (DLBCL) hasn’t changed in a decade. New treatment strategies for this type of blood cancer are urgently needed. Could the…
9 May 2018
Sharing this exciting news: a treatment advance for childhood leukaemia
A deal has been struck to let the NHS offer children an expensive new cancer therapy that has been called the most exciting treatment advance for decades